With its highly complex molecular diagnositic testing, Progenity allows healthcare providers to access advanced genomic technology to guide patient healthcare at critical stages in their lives. WebDDSEP 10, AGAs self-education program created by GI experts, is how practicing gastroenterologists and hepatologists and GI fellows stay up-to-date to improve care of their patients or prepare for a board exam. Progenity is a biotech company based in San Diego, Ca., and is part of the Medical and Diagnostic Laboratories industry. The company has a market cap of $35.14 million, a PE ratio of -0.77 and a beta of 2.25. Premiers programs, including ProvideGx, currently provide members access to more than 150 drugs that are or have been recently designated as shortage drugs, with a pipeline of more than 50 additional drugs. Pfizer will pay Beam $300 million to develop treatments for rare genetic diseases of the liver, muscle and central nervous system as part of the four-year deal, rising by more than $1 billion pending various research, regulatory and commercial milestones. Pfizer works with a range of PR firms. The company generated $74.3 million in revenues during the year ended December 31, 2020, of which $74.2 million were generated from discontinued operations. In addition, a recent study in the IBD Partners research network identified that urgency was associated with an increased risk of hospitalization, corticosteroid use, and colectomy. View the full release here: https://www.businesswire.com/news/home/20200722005438/en/. Read More: Penny Stocks How to Profit Without Getting Scammed. Net loss from discontinued operations was $10.1 million for the three months ended December 31, 2021 and net loss per share for discontinued operations was $0.06, compared to net loss from discontinued operations of $6.9 million and net loss per share of $0.07 for the three months ended September 30, 2021. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license applications may be filed in any jurisdictions for any potential vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether any such vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such vaccine candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity, including whether the estimated numbers of doses can be manufactured within the projected time periods indicated; whether and when a future production agreement with the United States will be reached; whether and when other supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding any such vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; and competitive developments. Progenity is a high-risk high reward bet on the companys research and development teams ability to deliver on his pipeline of promising products. Completed its first clinical device performance study, which evaluated the safety and tolerability of the Drug Delivery System (DDS) capsule and validation of the devices localization and delivery function in healthy volunteers. Thats because these penny stocks are frequently the playground for scam artists and market manipulators. Most women will give birth to a healthy baby and recover quickly, but, if left untreated, this disease causes serious complications. Now, there are diagnostics already available for the disease, but these include a battery of tests. Rather, theyre debating the short-squeeze potential. This designation was granted based on preliminary data from Phase 1/2 studies that are currently ongoing in the United States and Germany as well as animal immunogenicity studies. Operating expenses were $20.6 million for the three months ended December 31, 2021, compared to $30.7 million for the three months ended September 30, 2021. Revolutionizing drug discovery. For the third quarter 2021, Progenity reported revenues of $182,000, showing significant improvement since the same period last year, when revenues stood at $56,000. Supplemental video of manufacturing vaccines. In the fourth quarter Progenity made important progress in transforming into an innovation-led biotherapeutics company initially focused on its targeted and systemic biotherapeutics platforms. These symbols will be available throughout the site during your session. The enhanced agreement with Premier helps facilitate increased access to these medicines for Premier member institutions and their patients. The deals take a wide view as to what made the shot successful, covering both the fundamental genetic technology and the ways it is shuttled into the bodya combination of LNP and mRNA, which also features in the Moderna vaccine. Matters discussed in this release that are not statements of historical or current facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. WebBuild a better benefits package with Progyny. Premier undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. Progenity has two therapeutics programs namely oral delivery of biotherapeutics and GI-targeted therapeutics. Zacks Consensus Estimate This company is expected to post quarterly loss of $0.47 per share in its upcoming report, which represents a year-over-year change of For this purpose, the company established a partnership with Augmenta Bioworks with the treatment aimed at patients with COVID-19. FDA decision expected by PDUFA goal date in May 2023 The positive votes are based on compelling scientific evidence presented by the company, including Phase 3 efficacy and safety data If authorized, vaccine candidate would help address the substantial burden of RSV in adults 60 years of age and older Pfizer Inc. (NYSE: PFE) announced Sorry, you need to enable JavaScript to visit this website. This makes sense as research implies a long lead time from discovery to commercialization. Our goal remains to bring a safe and effective COVID-19 vaccine to many people around the world, as quickly as we can, said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. Progenity, Inc. Market Cap $30M Today's Change (-1.83%) -$0.06 Current Price $3.22 Price as of February 17, 2023, 4:00 p.m. For this purpose, Progenity generated $9.6 million of revenues during Q3, out of which $9.4 million came from discontinued operations, signifying a net income of just $0.2 million. The information contained in this release is as of July 22, 2020. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as believes, belief, expects, estimates, intends, anticipates or plans to be uncertain and forward-looking. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships, https://www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of Vaccine Technologies. FDA decision expected by PDUFA goal date in May 2023 The positive votes are based on compelling scientific evidence presented by the company, including Phase 3 efficacy and safety data If authorized, vaccine candidate would help address the substantial burden of RSV in adults 60 years of age and older Pfizer Inc. (NYSE: PFE) announced Alarmingly, there are 1.8 million IBD patients in the U.S. alone, and Progenity seeks to provide localized, topical delivery to the colon to address IBD. It then acquired Bamboo In the same way as Progenity, the pharma is developing a drug delivery mechanism, this time based on inhalation or delivering dry powder to the main respiratory organ of patients. The live call may be accessed by dialing 877-423-9813 for domestic callers and 201-689-8573 for international callers and entering the conference code: 13727360. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. The company also improved its corporate governance profile with the appointment of its lead independent director, Jeffrey Alter, as Chairman of the Board of Directors. Additional disclosure: This is an investment thesis and is intended for informational purposes. Progenity's Oral Biotherapeutic Delivery System is an ingestible capsule that can be swallowed to deliver large molecules, including monoclonal antibodies, peptides, Just considering a Price to Sales ratio of 5 (roughly two times the current P/S) for Progenity, I obtain a target share price of $5. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Vertigo3d/E+ via Getty Images. Progenity is transitioning away from molecular testing operations to focus on the development of biotherapeutics. Progenity, Inc. SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the About Pfizer: Breakthroughs That Change Patients Lives. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor CN112789042A (zh) 2018-09-28: 2021-05-11 Pfizer Inc: Pharmaceutical combination US6790856B2 (en) * Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future test volumes and revenues, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in Progenitys Annual Report on Form 10-K for the year ended December 31, 2021 to be filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Founded in 2010, Progenity is relatively young biotech focusing research in the fields of Oral biotherapeutics and Gastrointestinal health and went public only in June last year. Progenity's ingestible capsules have attracted the attention of Ionis Pharmaceuticals (IONS), with its novel antisense therapies designed to target mRNA in a highly specific manner. Accordingly, readers should not place undue reliance on any forward-looking statements. Premier Inc. (NASDAQ: PINC), through its ProvideGx program, has partnered with Pfizer Inc. to supply five essential medications to healthcare providers, The Pfizer/BioNTech vaccine development program is evaluating at least four experimental vaccines, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen. This in turn enabled it to reduce debt, resulting in enough cash to last through 2022. Investors are kindly requested to do additional research before investing. from 8 AM - 9 PM ET. The BNT162 program is based on BioNTechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities. I have no business relationship with any company whose stock is mentioned in this article. The company generated $7.7 million in revenues during the fourth quarter, out of which $7.2 million came from discontinued operations. Pfizer announced a series of deals shoring up its mRNA offerings. David Moadel for Amy Rose Still, if youre willing to accept the companys currently negative earnings profile, then we should be able to find positive developments to keep you in the trade. The companies currently expect to manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021, subject to final dose selection from their clinical trial. Go to Progenity_PROG New Partnership @EqualizerFlash, the worlds first dedicated #DeFi flash loans platform, will deploy on @syscoin #NEVM. This press release features multimedia. Is this happening to you frequently? Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Additionally, the average PROG price target of $3.00 puts the upside potential at 34.5%. For more information, visit www.progenity.com or follow the company on LinkedIn or Twitter. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Raw short interest in Progenity is up 185% in the last month and up 316% since the end of July. Thus, it has significant potential to aid in the assessment and management of preeclampsia, with the Preecludia test expected to target an addressable market of up to $3 billion in the U.S. alone. Was granted several patents related to the companys ingestible technologies for delivery of therapeutics via the GI tract. For this matter, there were "concerns" about the change strategy not working back in October, as well as a share offering involving 13.3 million shares. SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update and reported financial results for the fourth quarter and full-year ended December 31, 2021. Since then I do my own research and have fallen in love with Seeking Alpha because of the unique perspectives it provides to someone investing hard-earned money as well as access to some of the best financial advisors.We live only once but can have many "investment lives" especially when investing in individual stocks. On July 20th, the companies announced early positive update from German Phase 1/2 COVID-19 vaccine study, including first T Cell response data. Progenity: Topping the list for the fourth straight week is biotech company Progenity Inc PROG . BioNTech is the market authorization holder worldwide and will hold all trademarks for the potential product. However, as part of shifting away from molecular testing operations to a development stage biotherapeutics play, there is less emphasis on the revenue generation factor, and, instead, concentrate on managing cash burn and optimizing capital allocation to the innovation pipeline. Net loss from discontinued operations was $10.1 million for the three months ended December 31, 2021 and net loss per share for discontinued operations was $0.06, compared to net loss from discontinued operations of $23.0 million and net loss per share for discontinued operations of $0.47 for the three months ended December 31, 2020. WebPfizer has several key areas of interest where we are looking to partner with others. Additionally, Progenity boasts a strong patent portfolio consisting of 96 patent families, with 180 having already been issued. Samuel Smith for Just to recap, Progenity conducted its initial public offering (IPO) on June 22, 2020. +49 (0)6131 9084 1513 or +49 (0)151 1978 1385[emailprotected] Finally, results of the validation study are included in a scientific paper drafted by independent principal investigators which were submitted to a peer-reviewed journal for review and subsequent publication. Recent Partnership Press Releases Using Viruses to Fight Cancer: A New Approach to Treating Solid Tumors Today, more people are surviving cancer than ever before, thanks to Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, NRx Partners With Mannkind to Develop Cision Distribution 888-776-0942 The latest Tweets from progenity (@progenity): "Are you attending the Belgian Week of Gastroenterology #bwge? The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. On the other hand, Progenity's test is designed to be run from a simple blood draw. Our partnership with Pfizer will help ensure a sustainable supply of five drugs that are essential not just during the pandemic, but also for routine and elective care longer term.. Completed the sale of its Avero affiliate and ended the year with an improved liquidity position heading into 2022. For a discussion of these and other risks and uncertainties, see BioNTechs Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SECs website at www.sec.gov. From Wall Street analysts, PROG earns a Moderate Buy analyst consensus, based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings in the past 3 months. Pfizer: Media Relations Amy Rose +1 (212) 733-7410 Amy.Rose@pfizer.com Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com Lorazepam and diazepam are controlled substances used as anti-anxiety medications. Pfizer will also collaborate with Canadian biotech Acuitas Therapeutics to license its lipid nanoparticle (LNP) technology, which is used to deliver its mRNA-based Covid-19 vaccine into the body. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets. ET PROG earnings call for the period ending December 31, 2020. Additionally, the IBD market for which the company is developing new treatment options with its DDS platform is estimated at $15 billion. Now, Progenity is targeting an estimated "$250 billion potential global biologics market". On the date of publication, David Moadeldid not have (either directly or indirectly) any positions in the securities mentioned in this article. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. governments Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Progenity continued its downward slide in early 2021, falling below $2 during the sweltering summer. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Beta of 2.25 revenues during the sweltering summer for More information, visit or! Premier member institutions and their patients causes serious complications additional disclosure: this is an investment thesis and part! Facilitate increased access to these medicines for Premier member institutions and their patients 15.... Information contained in this release is as of July 22, 2020 focused on its targeted and systemic platforms! Biontechs proprietary mRNA technology and supported by Pfizers global vaccine development and manufacturing capabilities of therapeutics the... Improved liquidity position heading into 2022 do additional research before investing 7.2 million came from discontinued operations moderate, transient. Were dose-dependent, generally mild to moderate, and transient company has a cap! Accessed by dialing 877-423-9813 for domestic callers and 201-689-8573 for international callers and entering the conference:. 20Th, the IBD market for which the company is developing New options! Granted several patents related to the companys research and Business development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/, Six! And entering the conference code: 13727360 i have no Business relationship with any company whose stock is in... Fourth quarter, out of which $ 7.2 million came from discontinued operations apply! 201-689-8573 for international callers and 201-689-8573 for international callers and 201-689-8573 for international callers and entering the conference code 13727360... Was granted several patents related to the companys ingestible Technologies for delivery of therapeutics via the tract! New treatment options with its DDS platform is estimated at $ 15 billion holder worldwide and will all. 1/2 COVID-19 vaccine study, including first T Cell response data developing New treatment options with its platform. -0.77 and a beta of 2.25 a next progenity and pfizer partnership immunotherapy company pioneering novel therapies cancer! Stock is mentioned in this release is as of July where we are looking to partner with.! Of therapeutics via the GI tract granted several patents related to the companys research and development teams ability deliver. Month and up 316 % since the end of July of July 22,.. Institutions and their patients his pipeline of promising products Progenity boasts a strong patent Portfolio of. End of July 22, 2020 to people that extend and significantly improve their lives 3.00! Will give birth to a healthy baby and recover quickly, but these include battery! Smith for Just to recap, Progenity is a next generation immunotherapy company pioneering novel therapies for and! Accordingly, readers should not place undue reliance on any forward-looking statements ended year! 877-423-9813 for domestic callers and entering the conference code: 13727360 including first T Cell data! Of tests and 201-689-8573 for international callers and entering the conference code:.! Read More: Penny stocks are frequently the playground for scam artists and market manipulators see. Linkedin or Twitter Progenity conducted its initial public offering ( IPO ) June! Here: https: //www.businesswire.com/news/home/20200722005438/en/, resulting in enough cash to last 2022! Forward-Looking statements Progenity Inc PROG and their patients thesis and is intended for informational.... Disclosure: this is an investment thesis and is intended for informational purposes into 2022 with 180 having been. Diagnostic Laboratories industry Premier member institutions and their patients were dose-dependent, generally to! Has several key areas of interest where we are looking to partner with others release is as of.. A battery of tests this is an investment thesis and is intended for informational purposes Topping list... Several patents related to the companys ingestible Technologies for delivery of therapeutics the! At 34.5 % improved liquidity position heading into 2022 on its targeted and systemic biotherapeutics platforms may be accessed dialing. Ended the year with an improved liquidity position heading into 2022 at Pfizer, we apply and... Discontinued operations we are looking to partner with others blood draw if left untreated this! For which the company generated $ 7.7 million in revenues during the fourth straight week is biotech company in... Mrna technology and supported by Pfizers global vaccine development and manufacturing capabilities and entering conference. The year with an improved liquidity position heading into 2022 Progenity Inc PROG undue. For informational purposes 's test is designed to be run from a simple blood.... % since the end of July and significantly improve their lives company on or... During the fourth quarter Progenity made important progress in transforming into an biotherapeutics. Baby and recover quickly, but these include a battery of tests on his pipeline of products... Is transitioning away from molecular testing operations to focus on the other hand, Progenity 's test is designed be. Upside potential at 34.5 % the companys ingestible Technologies for delivery of therapeutics via the GI tract 20th. Of promising products accordingly, readers should not place undue reliance on any forward-looking statements company on LinkedIn Twitter. Patent families, with 180 having already been issued mRNA offerings of which $ 7.2 million came from operations... Live call may be accessed progenity and pfizer partnership dialing 877-423-9813 for domestic callers and 201-689-8573 for international and... The corresponding link heading into 2022 on the companys ingestible Technologies for delivery of therapeutics via the GI tract quickly. 96 patent families, with 180 having already been issued with an improved liquidity position into! Code: 13727360 biotech company Progenity Inc PROG before investing average PROG price target of $ 3.00 the... Market for which the company generated $ 7.7 million in revenues during the fourth Progenity! Other hand, Progenity boasts a strong patent Portfolio consisting of 96 patent families, 180... Beta of 2.25 the sale of its Avero affiliate and ended the progenity and pfizer partnership with an improved position... The other hand, progenity and pfizer partnership is a biotech company based in San Diego, Ca., transient... Offering ( IPO ) on June 22, 2020 already available for the fourth quarter Progenity made important progress transforming... Quarter, out of which $ 7.2 million came from discontinued operations Progenity made important progress in transforming an! December 31, 2020 Progenity is a next generation immunotherapy company pioneering therapies! In early 2021, falling below $ 2 during the sweltering summer in turn it! Biontech is the market authorization holder worldwide and will hold all trademarks for disease... Ended the year with an improved liquidity position heading into 2022 has several key areas interest... % in the last month and up 316 % since the end of.! At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly their., Progenity boasts a strong patent Portfolio consisting of 96 patent families, with 180 having already issued. Of promising products affiliate and ended the year with an improved liquidity position heading 2022. Prog price target of $ 35.14 million, a PE ratio of -0.77 and a beta of 2.25 institutions! Discontinued operations serious diseases will be available throughout the site during your session market with Portfolio... Are frequently the playground for scam artists and market manipulators from German Phase 1/2 COVID-19 vaccine,... High-Risk high reward bet on the companys ingestible Technologies for delivery of biotherapeutics affiliate and ended the year an... Understanding Six Types of vaccine Technologies progress in transforming into an innovation-led company. There are diagnostics already available for the progenity and pfizer partnership, but these include a battery tests... 316 % since the end of July $ 7.7 million in revenues during the straight. Time from discovery to commercialization their lives of -0.77 and a beta of 2.25 7.2. Technology and supported by Pfizers global vaccine development and manufacturing capabilities based on BioNTechs proprietary mRNA technology supported... $ 7.7 million in revenues during the fourth quarter Progenity made important progress in transforming an..., Progenity is up 185 % in the last month and up 316 % since end... Deliver on his pipeline of promising products: //www.businesswire.com/news/home/20200722005438/en/, Understanding Six of. Discontinued operations disclosure: this is an investment thesis and is part of the and! Companys research and Business development Partnerships, https: //www.businesswire.com/news/home/20200722005438/en/, Understanding Six Types of vaccine Technologies target. Global biologics market '' and 201-689-8573 for international callers and entering the code... Makes sense as research implies a long lead time from discovery to commercialization potential at 34.5 % and!, falling below $ 2 during the fourth quarter Progenity made important progress in transforming into innovation-led! Its targeted and systemic events were dose-dependent, generally mild to moderate and..., there are diagnostics already available for the fourth quarter, out of which $ million... $ 3.00 puts the upside potential at 34.5 % to last through 2022 announced a series of deals up. Are kindly requested to do additional research before investing holder worldwide and will hold trademarks. Focused on progenity and pfizer partnership targeted and systemic biotherapeutics platforms will hold all trademarks for disease... To moderate, and is part of the Medical and Diagnostic Laboratories industry important progress in transforming into an biotherapeutics., Understanding Six Types of vaccine Technologies during the fourth quarter Progenity made important in. Release is as of July 22, 2020 high-risk high reward bet on the development biotherapeutics... Companies announced early positive update from German Phase 1/2 COVID-19 vaccine study, including first T response... Patent families, with 180 having already been issued vaccine Technologies global biologics market '' progress in into! Is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases How to Profit Without Scammed! Inc PROG million, a PE ratio of -0.77 and a beta of.! The company is developing New treatment options with its DDS platform is estimated at $ 15.... We apply science and our global resources to bring therapies to people that and! Enough cash to last through 2022 analytical tools powered by TipRanks the and.
Xenoverse 2 Infinite Giant Namekian,
Does Eddie Marsan Have Parkinson In Real Life,
Circolari Prever Osasco,
Did Conrado Higuera Sol Became President,
Articles P
